The global AI in biotechnology market was valued at USD 3.23 billion in 2024 and is projected to reach USD 14.97 billion by 2033, growing at a compound annual growth rate (CAGR) of 21.1% over the forecast period. This growth is driven by the rising volume of biological data, increasing demand for accelerated drug discovery, and the expanding need for personalized medicine solutions. The report, titled "AI in Biotechnology Market - Global Industry Size, Share, Growth, Trends, Opportunity, and Forecast, 2025-2033," provides a comprehensive analysis of market dynamics, emerging trends, key opportunities, and competitive landscape across the biotechnology sector. It highlights how artificial intelligence is transforming drug development, genomics, biomarker discovery, and clinical trial optimization. Advancements in high-throughput sequencing, imaging technologies, and electronic health records have generated vast amounts of complex biological data. AI-powered tools are increasingly essential for processing, analyzing, and deriving actionable insights from this data at scale. Machine learning algorithms are enabling researchers to identify novel drug targets, predict protein structures, and simulate molecular interactions with unprecedented speed and accuracy. The push for personalized medicine is also a major driver, as AI helps tailor treatments based on individual genetic profiles, lifestyle factors, and disease progression. This shift is accelerating the development of targeted therapies and improving patient outcomes. Key players in the biotech and pharmaceutical industries are investing heavily in AI integration, partnering with specialized startups and technology firms to enhance R&D efficiency. Additionally, cloud-based AI platforms and open-source tools are lowering barriers to entry and fostering innovation across academic and commercial research institutions. Geographically, North America remains the largest market due to strong R&D infrastructure, significant venture capital funding, and early adoption of AI technologies. However, the Asia-Pacific region is expected to witness the fastest growth, fueled by government initiatives, expanding biotech ecosystems, and increasing investments in digital health. Challenges such as data privacy, regulatory uncertainty, and the need for high-quality training datasets remain, but ongoing efforts to standardize data formats and improve model transparency are helping to address these concerns. As AI continues to reshape the biotechnology landscape, its role in reducing time-to-market for new therapies, cutting R&D costs, and enabling precision medicine will become increasingly vital. The market’s robust growth trajectory underscores the transformative potential of AI in advancing human health and accelerating scientific discovery.